| Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer (NCT01780545) | Noah Hahn, M.D. | 2013-04-01 |
| Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study (NCT02298998) | The University of Texas Health Science Center at San Antonio | 2013-03-01 |
| Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression (NCT01732107) | Noah Hahn, M.D. | 2013-03-01 |
| Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers (NCT04723121) | Mansoura University | 2013-03-01 |
| Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy (NCT06170177) | IRCCS San Raffaele | 2013-02-04 |
| Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer (NCT01812369) | University Hospital, Rouen | 2013-02-01 |
| Improving Sensitivity of Urine Cytology for Bladder Cancer (NCT01826097) | Johns Hopkins University | 2013-01-01 |
| Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) (NCT01675219) | Turku University Hospital | 2012-12-01 |
| Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer (NCT01700010) | University of Michigan Rogel Cancer Center | 2012-11-01 |
| Evaluation of Ultrasound Probe for Use in Bladder Radiotherapy (NCT01698359) | University Hospital Birmingham NHS Foundation Trust | 2012-11-01 |
| Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer (NCT01688414) | Stanford University | 2012-09-01 |
| Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) (NCT01663285) | University of Michigan Rogel Cancer Center | 2012-09-01 |
| PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors (NCT01567462) | Emory University | 2012-09-01 |
| Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer (NCT01655745) | UNC Lineberger Comprehensive Cancer Center | 2012-07-24 |
| Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer (NCT01776138) | UNC Lineberger Comprehensive Cancer Center | 2012-07-23 |
| Mind-Body Health in Uro-Oncology: Research Study (NCT03852030) | Northwestern University | 2012-07-01 |
| Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer (NCT01627197) | Sun Yat-sen University | 2012-06-01 |
| Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer (NCT01840137) | University of Michigan | 2012-06-01 |
| Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy (NCT01622660) | Memorial Sloan Kettering Cancer Center | 2012-06-01 |
| Efficacy of Diclofenac BCG Irrigations (NCT01542567) | Carmel Medical Center | 2012-05-01 |
| Radical Cystectomy, Nutrition and Convalescence (NCT02238886) | Rigshospitalet, Denmark | 2012-05-01 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (NCT01844947) | Dr Anders Ullén | 2012-05-01 |
| Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer (NCT01589094) | Memorial Sloan Kettering Cancer Center | 2012-04-01 |
| Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy (NCT02039310) | University of Michigan | 2012-03-01 |
| Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer (NCT01563796) | Medical Diagnostic Laboratories, LLC | 2012-03-01 |
| Intravesical Thermochemotherapy With Mitomycin-c (NCT03694535) | TC Erciyes University | 2012-01-01 |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients (NCT01498172) | Patrice Jichlinski | 2012-01-01 |
| Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors (NCT01496534) | Matthew Galsky | 2012-01-01 |
| Detection of Bladder Tumors After 30 Min Instillation of Hexvix (NCT01551407) | Photocure | 2011-12-01 |
| Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer (NCT01738815) | State University of New York - Upstate Medical University | 2011-12-01 |
| Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer (NCT01373294) | H. Lee Moffitt Cancer Center and Research Institute | 2011-11-30 |
| S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer (NCT01224665) | SWOG Cancer Research Network | 2011-11-25 |
| The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer (NCT01489800) | Columbia University | 2011-11-01 |
| Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) (NCT01475266) | Nippon Kayaku Co., Ltd. | 2011-11-01 |
| Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia (NCT01444456) | Amgen | 2011-10-01 |
| Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer (NCT01395225) | University of British Columbia | 2011-08-01 |
| Safety Study of MGA271 in Refractory Cancer (NCT01391143) | MacroGenics | 2011-07-01 |
| Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer (NCT01410565) | Spectrum Pharmaceuticals, Inc | 2011-07-01 |
| Safety and Pharmacokinetic Study of EO9(Intravesical Instillation) (NCT01373398) | Handok Inc. | 2011-05-01 |
| A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT01314664) | Endo USA Inc., a Keenova Therapeutics Company | 2011-05-01 |
| 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer (NCT01162785) | M.D. Anderson Cancer Center | 2011-04-01 |
| Multimodal Rehabilitation Program to Bladder Cancer Patients (NCT01329107) | University of Aarhus | 2011-04-01 |
| To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer (NCT01284348) | Merck Sharp & Dohme LLC | 2011-03-25 |
| Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma (NCT01331824) | Matthew Galsky | 2011-02-01 |
| Neobladder Posterior Wall Suspended With Round Ligament of Uterus (NCT01273987) | Zhiwen Chen | 2011-01-01 |
| RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder (NCT01259063) | Memorial Sloan Kettering Cancer Center | 2010-12-01 |
| Feasibility of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer (NCT01142102) | Trans Tasman Radiation Oncology Group | 2010-10-01 |
| Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder (NCT01222676) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2010-10-01 |
| Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer (NCT01180478) | Clinical Research Office of the Endourological Society | 2010-08-01 |
| Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker (NCT01198808) | Technical University of Munich | 2010-08-01 |
| Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies (NCT01182168) | Memorial Sloan Kettering Cancer Center | 2010-08-01 |
| Salvage Docetaxel for Pretreated Urothelial Cancer (NCT01711112) | Samsung Medical Center | 2010-08-01 |
| Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer (NCT01240824) | University of Virginia | 2010-07-01 |
| Cancer in Patients With Gabapentin (GPRD) (NCT01236053) | GlaxoSmithKline | 2010-06-01 |
| Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer (NCT01191892) | Cardiff University | 2010-06-01 |
| Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB (NCT01166230) | Photocure | 2010-06-01 |
| Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer (NCT01126749) | Eisai Inc. | 2010-04-16 |
| Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer (NCT01108055) | Sandy Srinivas | 2010-04-01 |
| Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy (NCT01104350) | Memorial Sloan Kettering Cancer Center | 2010-04-01 |
| A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) (NCT01094496) | Celldex Therapeutics | 2010-04-01 |
| Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (NCT01459653) | Sandoz | 2010-03-01 |
| Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit (NCT01087697) | Tengion | 2010-03-01 |
| Randomized Trial Comparing Robotic and Open Radical Cystectomy (NCT01076387) | Memorial Sloan Kettering Cancer Center | 2010-02-01 |
| First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC (NCT01284205) | Bioniche Life Sciences Inc. | 2010-01-01 |
| Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study) (NCT01082510) | Urological Oncology Council of Northern Tokyo | 2010-01-01 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment (NCT01031875) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2009-12-01 |
| Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Perioperative Outcome in Patients Undergoing Radical Cystectomy (NCT01276665) | Insel Gruppe AG, University Hospital Bern | 2009-11-01 |
| Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer (NCT00995488) | University of Michigan Rogel Cancer Center | 2009-10-01 |
| Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer (NCT01094964) | Cancer Research Campaign Clinical Trials Centre | 2009-10-01 |
| Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer (NCT01170299) | Royal Marsden NHS Foundation Trust | 2009-10-01 |
| Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer (NCT00729287) | KU Leuven | 2009-09-01 |
| Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy (NCT01042795) | University of Michigan | 2009-09-01 |
| Urine Cytology and Utility in Bladder Recurrence (NCT00971256) | Corewell Health East | 2009-09-01 |
| Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients (NCT00974818) | Memorial Sloan Kettering Cancer Center | 2009-09-01 |
| 3 Tesla MRI in Patients With Bladder Cancer (NCT00938145) | University of Cincinnati | 2009-07-08 |
| Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma (NCT00933374) | Heinrich-Heine University, Duesseldorf | 2009-07-01 |
| Biomarker Discovery and Application in Bladder Cancer (NCT00962052) | Wolfson Medical Center | 2009-07-01 |
| A Study for Treatment of Superficial Bladder Cancer Using OGX-427 (NCT00959868) | Vancouver Coastal Health | 2009-07-01 |
| Acceptability of Less Harmful Alternatives to Cigarettes (NCT00957424) | Roswell Park Cancer Institute | 2009-06-01 |
| Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer (NCT00880854) | University of Wisconsin, Madison | 2009-06-01 |
| A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer (NCT00918008) | Memorial Sloan Kettering Cancer Center | 2009-06-01 |
| 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder (NCT01124682) | Institute of Cancer Research, United Kingdom | 2009-05-01 |
| A Genotype-Phenotype Urothelial Cancer Registry (NCT00902590) | Memorial Sloan Kettering Cancer Center | 2009-05-01 |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) (NCT01089088) | Cardiff University | 2009-04-01 |
| Comparison of Standard of Care or Treatment on Protocol (NCT01010334) | New Mexico Cancer Research Alliance | 2009-03-01 |
| Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NCT00847015) | Memorial Sloan Kettering Cancer Center | 2009-02-01 |
| Adaptive Planning in Bladder Cancer (NCT01000129) | Royal Marsden NHS Foundation Trust | 2009-01-01 |
| Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer (NCT01087268) | Royal Marsden NHS Foundation Trust | 2009-01-01 |
| Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer (NCT01196403) | Wales Cancer Trials Unit | 2009-01-01 |
| Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium (NCT00805129) | Memorial Sloan Kettering Cancer Center | 2008-12-05 |
| Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer (NCT00792025) | Institut Curie | 2008-12-01 |
| Recurrence of Bladder Cancer After Transurethral Resection With Hexvix (NCT00785694) | GE Healthcare | 2008-12-01 |
| Intravesicular Abraxane for Treatment-Refractory Bladder Cancer (NCT00583349) | Columbia University | 2008-12-01 |
| Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery (NCT00777491) | Radiation Therapy Oncology Group | 2008-12-01 |
| The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease (NCT00829920) | University of Colorado, Denver | 2008-11-01 |
| Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device? (NCT00802633) | Vanderbilt University | 2008-11-01 |
| Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health (NCT00776178) | National Cancer Institute (NCI) | 2008-10-17 |
| Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 (NCT01015963) | Alliance for Clinical Trials in Oncology | 2008-10-01 |
| Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder (NCT00694798) | Cadila Pharnmaceuticals | 2008-10-01 |
| Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology (NCT00801762) | Stanford University | 2008-09-01 |